A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent Rlp2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years.

Trial Profile

A Phase 2, Randomized, Placebo-Controlled, Single-blind Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent Rlp2086 Vaccine When Administered in Either 2- or 3-Dose Regimens in Healthy Subjects Aged ≥11 to <19 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 May 2017

At a glance

  • Drugs PF 5212366 (Primary)
  • Indications Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 30 May 2017 According to a Pfizer media release, the European Commission (EC) has approved TRUMENBA (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older. Results from this study supported the approval.
    • 12 May 2014 According to the Pfizer media release, the trial results were presented at the 32nd Annual Meeting of the European Society for paediatric Infectious Disease (EPID 2014).
    • 08 May 2014 Results of this trial were presented at the European Society for paediatric Infectious Disease (EPID 2014).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top